list of glp 1 agonists current GLP-1 and its analogs [36-39] glp 1 drug names list

In 2014, the FDA approved the first of these drugs specifically for weight loss for people with a BMI of 30 and above or a BMI of at least 27 with one weight-related comorbid disease, which affects more than half the U.S

4 For example, ADA and KDIGO joint group has recommended that for patients with T2DM and CKD who do not achieve their glycemic target with metformin and/or an SGLT2i or cannot use them, a GLP-1RAs with proven cardiovascular benefit is recommended

Most symptoms are gastrointestinal and typically occur during the first few weeks of treatment or following a dosage increase

Clinical Trial Results SURMOUNT-1 trial: Average weight loss of ~20% of total body weight

16 Particularly the effects of these medications have covered importance in diseases closely related to obesity and DM such as CKD, cardiovascular disease and MASH

52 These results, in part, supported the development of orforglipron as an orally delivered GLP-1RA in clinical testing